基本信息:
- 专利标题: 置換ベンジルアミン化合物および医療、特にC型肝炎ウイルス(HCV)感染症の治療におけるその使用
- 专利标题(英):Substituted benzyl amine compounds and medical care, in particular its use in the treatment of c hepatitis virus (hcv) infection
- 申请号:JP2014537662 申请日:2012-10-31
- 公开(公告)号:JP2015501315A 公开(公告)日:2015-01-15
- 发明人: ウッドヘッド,アンドリュー,ジェームズ , チェッサリ,ジャンニ , ベソング,ギルベルト,エバイ , カー,マリア,グラチア , ヒスコック,スティーブン,ダグラス , オーブライエン,マイケル,アリステア , リーズ,ダイビッド,チャールズ , サーロウ−ベセル,スザンヌ,マリア , ウィレムス,ヘンドリカ,マリア,ジェラルダ , トンプソン,ニール,トーマス
- 申请人: アステックス セラピューティックス リミテッド , アステックス セラピューティックス リミテッド
- 专利权人: アステックス セラピューティックス リミテッド,アステックス セラピューティックス リミテッド
- 当前专利权人: アステックス セラピューティックス リミテッド,アステックス セラピューティックス リミテッド
- 优先权: GB201118876 2011-11-01
- 主分类号: C07C217/58
- IPC分类号: C07C217/58 ; A61K31/135 ; A61K31/16 ; A61K31/18 ; A61K31/223 ; A61K31/27 ; A61K31/277 ; A61K31/337 ; A61K31/34 ; A61K31/343 ; A61K31/35 ; A61K31/357 ; A61K31/397 ; A61K31/40 ; A61K31/4035 ; A61K31/404 ; A61K31/415 ; A61K31/4164 ; A61K31/421 ; A61K31/4245 ; A61K31/428 ; A61K31/433 ; A61K31/437 ; A61K31/44 ; A61K31/4409 ; A61K31/4412 ; A61K31/4462 ; A61K31/4465 ; A61K31/472 ; A61K31/495 ; A61K31/4965 ; A61K31/50 ; A61K31/505 ; A61K31/537 ; A61K31/538 ; A61K31/551 ; A61K45/00 ; A61P31/12 ; A61P31/14 ; A61P43/00 ; C07C217/60 ; C07C237/06 ; C07C237/08 ; C07C237/10 ; C07D205/02 ; C07D207/09 ; C07D207/335 ; C07D209/08 ; C07D209/14 ; C07D209/44 ; C07D211/26 ; C07D211/56 ; C07D211/70 ; C07D211/76 ; C07D213/38 ; C07D213/64 ; C07D213/73 ; C07D213/74 ; C07D213/75 ; C07D217/02 ; C07D231/12 ; C07D233/24 ; C07D233/64 ; C07D237/14 ; C07D239/32 ; C07D239/42 ; C07D241/18 ; C07D243/08 ; C07D263/32 ; C07D265/36 ; C07D271/10 ; C07D277/68 ; C07D285/13 ; C07D295/18 ; C07D305/08 ; C07D307/22 ; C07D307/79 ; C07D309/04 ; C07D309/06 ; C07D319/18 ; C07D513/04
The present invention of formula (I):
[Formula 1]
The compound or a salt thereof, to provide a N- oxide or tautomer thereof, wherein, A is CH, be CF or nitrogen; E is CH, be CF or nitrogen;
R 0 is hydrogen or
C. 1 to is
2-alkyl; R 1a
is, CONH 2;
CO 2 H; optionally substituted by are acyclic
C 1 to 8 hydrocarbon group; a and ring members 3-7, 0 of which one , two, three or four is O, a heteroatom ring members selected from N and S, selected from a monocyclic carbocyclic or heterocyclic group are optionally substituted; R
2 is hydrogen and is selected from the group
R 2a; R 2a is acyclic d--. 8 hydrocarbon group which is optionally substituted; the ring members 3-7, 0 of which one or two ring members O, heteroatom ring members selected from N and S, monocyclic carbocyclic or heterocyclic group are optionally substituted; a and ring members 9 or 10, one or two of them ring members is a nitrogen atom, is selected from a bicyclic heterocyclic group which is optionally substituted; at least one of R
1 and R
2 is other than hydrogen; R
3 is, N, O and S 0 hetero ring members chosen, be one, two or three comprise, optionally substituted, 3-10 membered monocyclic or bicyclic carbocyclic or heterocyclic ring; R
4a is a halogen; cyano;
C 1 to 4 which is optionally substituted with one or more fluorine atoms alkoxy; one or more
C 1 to 4 alkyl which is optionally substituted with fluorine atoms hydroxy
-C. 1 to It is selected from and
C 1 to 2 alkoxy
-C 1 to 4 alkyl;
4 alkyl
R 5 is selected from hydrogen and substituents
R 5a; R 5a is, C that is optionally substituted with one or more fluorine atoms
1-2 alkyl; halogen; cyclopropyl; one or more C
1 to 3 alkoxy optionally substituted with fluorine atoms is selected from and amino; cyano. The compounds have activity against hepatitis C virus is one that can be used for prophylaxis or treatment of hepatitis C virus infection.
.BACKGROUND